NVCR NovoCure Ltd
Nasdaq · SEC CIK 1645113 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $3.25M 20 sales by 14 insiders
- Filings on record
- 265 since 2021-07-08, latest 2026-07-01 16:33
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| Paravasthu Mukund | COO | — | $693.8K |
| Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| Brackmann Christoph | CFO | — | $85.3K |
| Stafford Kristin | Dir | — | $46.4K |
| Ocean Allyson J | Dir | — | $46.4K |
| Scannell Timothy J | Dir | — | $46.4K |
| VERNON W ANTHONY | Dir | — | $46.4K |
| Hung David | Dir | — | $46.4K |
Transactions 293
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-15 | 2025-01-11 | NVCR | Paravasthu Mukund | COO | S - Sale | $26.81 | -2,160 | 31.4K | -6% | -$57.9K | |
| M | 2025-01-03 | 2024-12-31+ | NVCR | Danziger Asaf | Dir | A - Grant | $0.0152 | +400.4K | 15.6K | New | +$6,077 |
| 2025-01-03 | 2024-12-31 | NVCR | Ben Arye Barak | GC | A - Grant | $14.75 | +669 | 118.7K | +0.6% | +$9,868 | |
| 2025-01-03 | 2024-12-31 | NVCR | Cordova Ashley | CEO | A - Grant | $14.75 | +373 | 219.6K | +0.2% | +$5,502 | |
| D | 2024-11-06 | 2024-11-04 | NVCR | Paravasthu Mukund | COO | A - Grant | $0.00 | +30.1K | 33.6K | +871% | $0 |
| D | 2024-11-06 | 2024-11-02 | NVCR | Paravasthu Mukund | COO | S - Sale | $16.69 | -44 | 3,459 | -1% | -$734.36 |
| 2024-11-04 | 2024-10-31 | NVCR | Puri Michal Nath | CHRO | S - Sale | $15.79 | -810 | 110.1K | -0.7% | -$12.8K | |
| 2024-11-04 | 2024-11-01 | NVCR | Paravasthu Mukund | COO | S - Sale | $15.88 | -160 | 3,503 | -4% | -$2,541 | |
| 2024-11-04 | 2024-11-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $15.94 | -598 | 161.2K | -0.4% | -$9,532 | |
| 2024-08-06 | 2024-06-28 | NVCR | Ben Arye Barak | GC | A - Grant | $12.24 | +930 | 118.1K | +0.8% | +$11.4K | |
| 2024-08-06 | 2024-06-28 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $12.24 | +1,736 | 161.8K | +1% | +$21.2K | |
| 2024-08-06 | 2024-06-28 | NVCR | Cordova Ashley | CFO | A - Grant | $12.24 | +1,286 | 220.5K | +0.6% | +$15.7K | |
| 2024-08-06 | 2024-06-28 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $12.24 | +1,055 | 252.3K | +0.4% | +$12.9K | |
| 2024-08-06 | 2024-06-28 | NVCR | Puri Michal Nath | CHRO | A - Grant | $12.24 | +1,736 | 110.9K | +2% | +$21.2K | |
| 2024-08-06 | 2024-06-28 | NVCR | Danziger Asaf | CEO, Dir | A - Grant | $12.24 | +1,239 | 15.2K | +9% | +$15.2K | |
| 2024-08-05 | 2024-08-02 | NVCR | Cordova Ashley | CFO | S - Sale | $20.14 | -688 | 219.2K | -0.3% | -$13.9K | |
| DI | 2024-06-07 | 2024-06-05 | NVCR | GROENHUYSEN WILHELMUS CM | COO | M - OptEx | $22.82 | +124.4K | 124.4K | New | +$2.84M |
| D | 2024-06-06 | 2024-06-05 | NVCR | Scannell Timothy J | Dir | A - Grant | $0.00 | +4,053 | 7,981 | +103% | $0 |
| D | 2024-06-06 | 2024-06-04 | NVCR | Scannell Timothy J | Dir | S - Sale | $23.89 | -964 | 2,964 | -25% | -$23.0K |
| D | 2024-06-06 | 2024-06-05 | NVCR | Ocean Allyson J | Dir | A - Grant | $0.00 | +4,053 | 4,053 | New | $0 |
| D | 2024-06-06 | 2024-06-05 | NVCR | Madden Martin J. | Dir | A - Grant | $0.00 | +4,053 | 19.7K | +26% | $0 |
| D | 2024-06-06 | 2024-06-05 | NVCR | Stafford Kristin | Dir | A - Grant | $0.00 | +4,053 | 4,053 | New | $0 |
| D | 2024-06-06 | 2024-06-05 | NVCR | HILLEMAN JERYL L | Dir | A - Grant | $0.00 | +4,053 | 6,590 | +160% | $0 |
| D | 2024-06-06 | 2024-06-04 | NVCR | VERNON W ANTHONY | Dir | S - Sale | $23.89 | -964 | 164.8K | -0.6% | -$23.0K |
| D | 2024-06-06 | 2024-06-05 | NVCR | VERNON W ANTHONY | Dir | A - Grant | $0.00 | +4,053 | 169.8K | +2% | $0 |
| D | 2024-06-06 | 2024-06-05 | NVCR | LEUNG GABRIEL | Dir | A - Grant | $0.00 | +4,053 | 83.2K | +5% | $0 |
| D | 2024-06-06 | 2024-06-04 | NVCR | LEUNG GABRIEL | Dir | S - Sale | $23.89 | -964 | 78.2K | -1% | -$23.0K |
| D | 2024-06-06 | 2024-06-05 | NVCR | Hung David | Dir | A - Grant | $0.00 | +4,053 | 13.2K | +44% | $0 |
| M | 2024-03-05 | 2024-03-01+ | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $16.02 | -3,324 | 251.2K | -1% | -$53.3K |
| M | 2024-03-05 | 2024-03-01+ | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $16.02 | -2,519 | 160.1K | -2% | -$40.4K |
| D | 2024-02-29 | 2024-02-27 | NVCR | Puri Michal Nath | CHRO | A - Grant | $16.30 | +71.6K | 109.2K | +190% | +$1.17M |
| DM | 2024-02-29 | 2023-12-31+ | NVCR | Ben Arye Barak | GC | A - Grant | $16.29 | +81.9K | 35.3K | New | +$1.33M |
| D | 2024-02-29 | 2024-02-27 | NVCR | Giladi Moshe | CSO | A - Grant | $16.30 | +51.1K | 69.8K | +274% | +$833.3K |
| D | 2024-02-29 | 2024-02-27 | NVCR | Leupin Nicolas | Chief Medical Off | A - Grant | $16.30 | +51.1K | 51.1K | New | +$833.3K |
| D | 2024-02-29 | 2024-02-27 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $16.30 | +102.2K | 164.7K | +164% | +$1.67M |
| D | 2024-02-29 | 2024-02-28 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $16.14 | -2,078 | 162.6K | -1% | -$33.5K |
| D | 2024-02-29 | 2024-02-27 | NVCR | Cordova Ashley | CFO | A - Grant | $16.30 | +102.2K | 219.9K | +87% | +$1.67M |
| D | 2024-02-29 | 2024-02-28 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $16.14 | -2,303 | 254.6K | -0.9% | -$37.2K |
| DM | 2024-02-29 | 2023-12-31+ | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $16.30 | +47.0K | 209.8K | +29% | +$766.7K |
| D | 2024-02-29 | 2024-02-27 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $16.30 | +81.8K | 171.1K | +92% | +$1.33M |
| 2023-11-08 | 2023-11-07 | NVCR | Shah Pritesh | Chief Growth Off | S - Sale | $12.65 | -382 | 124.5K | -0.3% | -$4,832 | |
| D | 2023-11-03 | 2023-10-31 | NVCR | Puri Michal Nath | CHRO | A - Grant | $0.00 | +37.6K | 37.6K | New | $0 |
| DM | 2023-11-02 | 2023-10-31+ | NVCR | Cordova Ashley | CFO | M - OptEx | $9.60 | +18.0K | 109.7K | +20% | +$172.5K |
| 2023-09-05 | 2023-09-01 | NVCR | Shah Pritesh | Chief Growth Off | S - Sale | $21.82 | -273 | 124.9K | -0.2% | -$5,957 | |
| 2023-09-05 | 2023-09-01 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $21.82 | -294 | 209.8K | -0.1% | -$6,415 | |
| 2023-09-05 | 2023-09-01 | NVCR | Cordova Ashley | CFO | S - Sale | $21.82 | -883 | 99.7K | -0.9% | -$19.3K | |
| 2023-08-04 | 2023-08-02 | NVCR | Cordova Ashley | CFO | S - Sale | $30.25 | -1,144 | 100.5K | -1% | -$34.6K | |
| 2023-07-06 | 2023-06-30 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $35.28 | +366 | 210.1K | +0.2% | +$12.9K | |
| 2023-07-06 | 2023-06-30 | NVCR | Cordova Ashley | CFO | A - Grant | $35.28 | +367 | 101.7K | +0.4% | +$12.9K | |
| 2023-07-06 | 2023-06-30 | NVCR | Ben Arye Barak | GC | A - Grant | $35.28 | +288 | 35.2K | +0.8% | +$10.2K | |
| 2023-07-06 | 2023-06-30 | NVCR | Burke William Patrick | CHRO | A - Grant | $35.28 | +357 | 66.4K | +0.5% | +$12.6K | |
| 2023-07-06 | 2023-06-30 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $35.28 | +305 | 89.3K | +0.3% | +$10.8K | |
| 2023-07-06 | 2023-06-30 | NVCR | Shah Pritesh | Chief Growth Off | A - Grant | $35.28 | +367 | 125.2K | +0.3% | +$12.9K | |
| 2023-07-06 | 2023-06-30 | NVCR | Danziger Asaf | CEO, Dir | A - Grant | $35.28 | +367 | 14.0K | +3% | +$12.9K | |
| D | 2023-06-09 | 2023-06-07 | NVCR | VERNON W ANTHONY | Dir | A - Grant | $0.00 | +3,853 | 165.8K | +2% | $0 |
| D | 2023-06-09 | 2023-06-07 | NVCR | LEUNG GABRIEL | Dir | A - Grant | $0.00 | +3,853 | 79.1K | +5% | $0 |
| D | 2023-06-09 | 2023-06-07 | NVCR | Scannell Timothy J | Dir | A - Grant | $0.00 | +3,853 | 3,928 | +5,137% | $0 |
| M | 2023-03-07 | 2023-03-03 | NVCR | Cordova Ashley | CFO | S - Sale | $76.16 | -5,505 | 102.1K | -5% | -$419.3K |
| M | 2023-03-07 | 2023-03-03+ | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.55 | -13.6K | 63.5K | -18% | -$1.03M |
| M | 2023-03-07 | 2023-03-03 | NVCR | Shah Pritesh | Chief Growth Off | S - Sale | $76.16 | -21.4K | 144.7K | -13% | -$1.63M |
| 2023-03-07 | 2023-03-03 | NVCR | Burke William Patrick | CHRO | S - Sale | $76.16 | -593 | 66.1K | -0.9% | -$45.2K | |
| M | 2023-03-07 | 2023-03-03 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $76.16 | -25.6K | 231.9K | -10% | -$1.95M |
| M | 2023-03-06 | 2023-03-03 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $0.00 | +52.0K | 231.5K | +29% | $0 |
| 2023-03-06 | 2023-03-02 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $75.28 | -1,213 | 183.4K | -0.7% | -$91.3K | |
| 2023-03-06 | 2023-03-02 | NVCR | Burke William Patrick | CHRO | S - Sale | $75.28 | -281 | 66.7K | -0.4% | -$21.2K | |
| 2023-03-06 | 2023-03-03 | NVCR | Leonard Frank X | Pres, CNS Cancers US | A - Grant | $0.00 | +11.8K | 70.0K | +20% | $0 | |
| M | 2023-03-06 | 2023-03-02+ | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.95 | -2,903 | 58.1K | -5% | -$223.4K |
| M | 2023-03-06 | 2023-03-03 | NVCR | Shah Pritesh | Chief Growth Off | A - Grant | $0.00 | +47.2K | 103.0K | +85% | $0 |
| 2023-03-06 | 2023-03-02 | NVCR | Shah Pritesh | Chief Growth Off | S - Sale | $75.28 | -937 | 99.0K | -0.9% | -$70.5K | |
| M | 2023-03-06 | 2023-03-03 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $0.00 | +32.8K | 89.0K | +58% | $0 |
| 2023-03-06 | 2023-03-02 | NVCR | Cordova Ashley | CFO | S - Sale | $75.28 | -1,055 | 95.0K | -1% | -$79.4K | |
| 2023-03-06 | 2023-03-03 | NVCR | Cordova Ashley | CFO | A - Grant | $0.00 | +11.8K | 106.8K | +12% | $0 | |
| M | 2023-03-03 | 2023-03-02 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.37 | -4,107 | 59.0K | -7% | -$309.6K |
| D | 2023-03-02 | 2023-02-28 | NVCR | Ben Arye Barak | GC | A - Grant | $0.00 | +17.8K | 34.9K | +104% | $0 |
| D | 2023-03-02 | 2023-02-28 | NVCR | Shah Pritesh | Chief Growth Off | A - Grant | $0.00 | +19.1K | 101.9K | +23% | $0 |
| D | 2023-03-02 | 2023-03-01 | NVCR | Shah Pritesh | Chief Growth Off | S - Sale | $76.36 | -1,923 | 100.0K | -2% | -$146.8K |
| D | 2023-03-02 | 2023-02-28 | NVCR | Burke William Patrick | CHRO | A - Grant | $0.00 | +12.1K | 67.7K | +22% | $0 |
| D | 2023-03-02 | 2023-03-01 | NVCR | Burke William Patrick | CHRO | S - Sale | $76.36 | -755 | 67.0K | -1% | -$57.7K |
| D | 2023-03-02 | 2023-03-01 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $76.36 | -2,164 | 184.6K | -1% | -$165.2K |
| D | 2023-03-02 | 2023-02-28 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $0.00 | +21.7K | 186.8K | +13% | $0 |
| D | 2023-03-02 | 2023-02-28 | NVCR | Cordova Ashley | CFO | A - Grant | $0.00 | +23.8K | 98.3K | +32% | $0 |
| D | 2023-03-02 | 2023-03-01 | NVCR | Cordova Ashley | CFO | S - Sale | $76.36 | -2,198 | 96.1K | -2% | -$167.8K |
| D | 2023-03-02 | 2023-02-28 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $0.00 | +13.0K | 56.3K | +30% | $0 |
| D | 2023-03-02 | 2023-02-28 | NVCR | Leonard Frank X | Pres, CNS Cancers US | A - Grant | $0.00 | +18.6K | 64.8K | +40% | $0 |
| D | 2023-03-02 | 2023-03-01 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.36 | -1,684 | 63.1K | -3% | -$128.6K |
| 2023-01-10 | 2023-01-06 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $62.31 | +102 | 165.1K | +0.1% | +$6,356 | |
| 2023-01-10 | 2023-01-06 | NVCR | Cordova Ashley | CFO | A - Grant | $62.31 | +66 | 74.4K | +0.1% | +$4,112 | |
| 2023-01-10 | 2023-01-06 | NVCR | Ben Arye Barak | GC | A - Grant | $62.31 | +150 | 17.2K | +0.9% | +$9,346 | |
| 2023-01-10 | 2023-01-06 | NVCR | Burke William Patrick | CHRO | A - Grant | $62.31 | +108 | 55.6K | +0.2% | +$6,729 | |
| 2023-01-10 | 2023-01-06 | NVCR | Benaim Ely | Chief Medical Off | A - Grant | $62.31 | +98 | 28.8K | +0.3% | +$6,106 | |
| D | 2023-01-09 | 2023-01-06 | NVCR | Danziger Asaf | CEO, Dir | A - Grant | $62.31 | +39 | 13.6K | +0.3% | +$2,430 |
| DM | 2023-01-09 | 2023-01-05 | NVCR | Danziger Asaf | CEO, Dir | S - Sale+OE | $108.73 | -212.5K | 15.4K | -93% | -$23.11M |
| DM | 2023-01-09 | 2023-01-05 | NVCR | Danziger Asaf | CEO, Dir | M - OptEx | $7.66 | +212.5K | 38.6K | New | +$1.63M |
| 2023-01-09 | 2023-01-05 | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $108.00 | -387 | 82.8K | -0.5% | -$41.8K | |
| DM | 2023-01-09 | 2023-01-05 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale+OE | $112.25 | -39.5K | 47.2K | -46% | -$4.43M |
| DM | 2023-01-09 | 2023-01-05 | NVCR | Leonard Frank X | Pres, CNS Cancers US | M - OptEx | $15.39 | +35.2K | 53.3K | +194% | +$541.7K |
| DM | 2023-01-09 | 2023-01-05 | NVCR | Weinberg Uri | CSO | S - Sale+OE | $116.14 | -8,143 | 47.1K | -15% | -$945.8K |
| D | 2023-01-09 | 2023-01-05 | NVCR | Weinberg Uri | CSO | M - OptEx | $47.04 | +1,946 | 49.0K | +4% | +$91.5K |
| D | 2022-12-05 | 2022-12-02 | NVCR | Cordova Ashley | CFO | M - OptEx | $7.15 | +2,000 | 74.4K | +3% | +$14.3K |
| D | 2022-11-03 | 2022-11-01 | NVCR | Leonard Frank X | Pres, CNS Cancers US | A - Grant | $0.00 | +6,830 | 50.5K | +16% | $0 |
Purchase Sale Sale after option exercise All abbreviations